26486 Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices 

industry and investment industry in 

order to increase innovation and 

investment in the healthcare sector? 

2. How the workgroup should be 

convened and structured, including 

what subsectors of the healthcare 

economy should be invited to 

participate, and the most effective size. 

How should the agency structure 

meetings or other engagements in order 

to best facilitate the exchange of 

information and the presentation of 

attendees’ individual perspectives? The 

Department seeks comment on how 

suitable attendees should be identified 

and selected to attend and engage in an 

exchange of ideas about the 

Department’s goals of increasing 

innovation and investment in the 

healthcare sector. 

3. HHS also seeks comment more 

broadly on opportunities for increased 

engagement and dialogue between HHS 

and those focused on innovating and 

investing in the healthcare industry, 

including alternatives to the workgroup 

structure discussed in this request for 

information. The Department is 

interested in comments that propose 

alternatives for developing a durable 

and consistent approach to increase 

innovation and investment in the 

healthcare sector to improve the public 

health and wellbeing of Americans. 

This is a request for information only. 

Respondents are encouraged to provide 

complete but concise responses to any 

or all of the questions outlined above. 

This request for information is issued 

solely for information and planning 

purposes; it does not constitute a notice 

of proposed rulemaking or request for 

proposals, applications, proposal 

abstracts, or quotations, nor does it 

suggest that the Department will 

undertake any particular action in 

response to comments. This request for 

information does not commit the United 

States Government (‘‘Government’’) to 

contract for any supplies or services or 

make a grant award. Further, HHS is not 

seeking proposals through this request 

for information and will not accept 

unsolicited proposals. Respondents are 

advised that the Government will not 

pay for any information or 

administrative costs incurred in 

response to this request for information; 

all costs associated with responding to 

this request for information will be 

solely at the interested party’s expense. 

Not responding to this request for 

information does not preclude 

participation in any future rulemaking 

or procurement, if conducted. It is the 

responsibility of the potential 

responders to monitor this request for 

information announcement for 

additional information pertaining to this 

request. We also note that HHS will not 

respond to questions about the policy 

issues raised in this request for 

information. HHS may or may not 

choose to contact individual responders. 

Such communications would only serve 

to further clarify written responses. 

Contractor support personnel may be 

used to review the responses submitted 

under this request for information. 

Responses to this notice are not offers 

and cannot be accepted by the 

Government to form a binding contract 

or issue a grant. Information obtained in 

response to this request for information 

may be used by the Government for 

program planning on a non-attribution 

basis. Respondents should not include 

any information that might be 

considered proprietary or confidential. 

This request for information should not 

be construed as a commitment or 

authorization to incur cost for which 

reimbursement would be required or 

sought. All submissions become 

Government property and will not be 

returned. HHS may publicly post the 

comments received, or a summary 

thereof. While responses to this request 

for information do not bind HHS to any 

further actions related to the response, 

all comments may be posted online on 

http://www.regulations.gov. 

III. Collection of Information 

This document does not impose 

information collection requirements; 

that is, reporting, recordkeeping or 

third-party disclosure requirements. 

This request for information constitutes 

a general solicitation of comments. In 

accordance with the implementing 

regulations of the Paperwork Reduction 

Act of 1995 (PRA) at 5 CFR 1320.3(h)(4), 

information subject to the PRA does not 

generally include ‘‘facts or opinions 

submitted in response to general 

solicitations of comments from the 

public, published in the Federal 

Register or other publications, 

regardless of the form or format thereof, 

provided that no person is required to 

supply specific information pertaining 

to the commenter, other than that 

necessary for self-identification, as a 

condition of the agency’s full 

consideration of the comment.’’ 

Consequently, this document need not 

be reviewed by the Office of 

Management and Budget under the 

authority of the PRA (44 U.S.C. 3501 et 

seq.). 

Authority: 42 U.S.C. 3501. 

Dated: June 1, 2018. 

Eric D. Hargan, 

Deputy Secretary, Department of Health and 

Human Services. 

[FR Doc. 2018–12234 Filed 6–6–18; 8:45 am] 

BILLING CODE 4150–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Arthritis and 

Musculoskeletal and Skin Diseases Initial 

Review Group; Arthritis and Musculoskeletal 

and Skin Diseases Special Grants Review 

Committee. 

Date: June 13–14, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites, Chevy Chase 

Pavilion, 4300 Military Rd. NW, Washington, 

DC 20015. 

Contact Person: Helen Lin, Ph.D., 

Scientific Review Officer, NIH/NIAMS/RB, 

6701 Democracy Blvd., Suite 800, Plaza One, 

Bethesda, MD 20817, 301–594–4952, linh1@

mail.nih.gov. 

Name of Committee: Arthritis and 

Musculoskeletal and Skin Diseases Initial 

Review Group; Arthritis and Musculoskeletal 

and Skin Diseases Clinical Trials Review 

Committee. 

Date: June 19, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, 1 Bethesda 

Metro Center, Bethesda, MD 20814. 

Contact Person: Nakia C Brown, Ph.D., 

Scientific Review Officer, 6701 Democracy 

Blvd., RM 816, Bethesda, MD 20892, 301– 

827–4905, brownnac@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices 26487 

Dated: June 1, 2018. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–12175 Filed 6–6–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: The Development of an 

Anti-BCMA Immunotoxin for the 

Treatment of Human Cancer 

AGENCY: National Institutes of Health, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the SUPPLEMENTARY INFORMATION

section of this notice to BEORO 

Therapeutics, GmbH. (‘‘Beoro’’) located 

in Seefeld, Germany. 

DATES: Only written comments and/or 

complete applications for a license 

which are received by the National 

Cancer Institute’s Technology Transfer 

Center on or before June 22, 2018 will 

be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: David A. Lambertson, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center, 9609 

Medical Center Drive, RM 1E530 MSC 

9702, Bethesda, MD 20892–9702 (for 

business mail), Rockville, MD 20850– 

9702 Telephone: (240)–276–5530; 

Facsimile: (240)–276–5504 Email: 

david.lambertson@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

The following represents the 

intellectual property to be licensed 

under the prospective agreement: 

U.S. Patent Application 62/255,255 

(HHS reference E–010–2016–0–US–01), 

U.S. Patent Application 62/257,493 

(HHS reference E–010–2016–1–US–01), 

and PCT Patent Application PCT/ 

US2016/061320 (HHS reference E–010– 

2016–2–PCT–01); 

U.S. Patent Application 61/887,418 

(HHS reference E–771–2013–0–US–01), 

U.S. Patent Application 61/908,464 

(HHS reference E–771–2013–1–US–01), 

U.S. Patent Application 61/982,051 

(HHS reference E–771–2013–2–US–01), 

U.S. Patent Application 61/052,665 

(HHS reference E–771–2013–3–US–01), 

PCT Application PCT/US2014/058941 

(HHS reference E–771–2013–4–PCT– 

01), U.S. Patent 9,388,222 (HHS 

reference E–771–2013–4–US–02), 

Australian Patent Application 

2014329437 (HHS reference E–771– 

2013–4–AU–08), Canadian Patent 

Application 2926215 (HHS reference E– 

771–2013–4–CA–09), Chinese Patent 

Application 201480062185.7 (HHS 

Reference E–771–2013–4–CN–10), 

European Patent Application 

14789449.7 (HHS reference E–771– 

2013–4–EP–11), Indian Patent 

Application 201647015226 (HHS 

reference E–771–2013–4–IN–12), 

Russian Patent Application 2016114406 

(HHS reference E–771–2013–4–RU–13), 

Japanese Patent Application (HHS 

reference E–771–2013–4–JP–14), and 

U.S. Patent Application 15/191,392 

(HHS reference E–771–2013–4–US–15); 

U.S. Patent Application 61/535,668 

(HHS reference E–263–2011–0–US–01), 

PCT Application PCT/US2012/055034 

(HHS reference E–263–2011–0–PCT– 

02), Australian Patent 2012308591 (HHS 

reference E–263–2011–0–AU–03), 

Canadian Patent Application 2846608 

(HHS reference E–263–2011–0–CA–04), 

European Patent 2755993 (HHS 

reference E–263–2011–0–EP–05), U.S. 

Patent 9,206,240 (HHS reference E–263– 

2011–0–US–06), Hong Kong Patent 

Application 14111650.2 (HHS reference 

E–263–2011–0–HK–07), U.S. Patent 

9,657,066 (HHS reference E–263–2011– 

0–US–08), U.S. Patent Application 15/ 

488,898 (HHS reference E–263–2011–0– 

US–09) and European Patent 

Application 14/927,645 (HHS reference 

E–263–2011–0–EP–18); 

U.S. Patent Application 61/495,085 

(HHS reference E–174–2011–0–US–01), 

PCT Application PCT/US2012/041234 

(HHS reference E–174–2011–0–PCT– 

02), Australian Patent 2012268013 (HHS 

reference E–174–2011–0–AU–03), 

Brazilian Patent Application 

112013031262–9 (HHS reference E– 

174–2011–0–BR–04), Canadian Patent 

Application 2838013 (HHS reference E– 

174–2011–0–CA–05), Chinese Patent 

Application 201280039071.1 (HHS 

reference E–174–2011–0–CN–06), 

European Patent 2718308 (HHS 

reference E–174–2011–0–EP–07) as 

validated in Germany, Spain, France, 

the United Kingdom, and Italy, Hong 

Kong Patent Application 14105911.9 

(HHS reference E–174–2011–0–HK–08), 

Japanese Patent 6100764 (HHS reference 

E–174–2011–0–JP–09), South Korean 

Patent Application 2013–7032402 (HHS 

reference E–174–2011–0–KR–10), 

Mexican Patent Application MX/a/ 

2013/014388 (HHS reference E–174– 

2011–0–MX–11), Russian Patent 

2627216 (HHS reference E–174–2011– 

0–RU–12), U.S. Patent 9,346,859 (HHS 

reference E–174–2011–0–US–13), Hong 

Kong Patent Application 14106689.7 

(HHS reference E–174–2011–0–HK–14), 

U.S. Patent 9,765,123 (HHS reference E– 

174–2011–0–US–15), Australian Patent 

Application 2017200541 (HHS reference 

E–174–2011–0–AU–16), European 

Patent Application 17163568.3 (HHS 

reference E–174–2011–0–EP–17), 

Japanese Patent Application 2017– 

031283 (HHS reference E–174–2011–0– 

JP–18), and U.S. Patent Application 15/ 

693,705 (HHS reference E–174–2011/0– 

US–24); 

U.S. Patent Application 61/241,620 

(HHS reference E–269–2009–0–US–01), 

PCT Application PCT/US2010/048504 

(HHS reference E–269–2009–0–PCT– 

02), Australian Patent 2010292069 (HHS 

reference E–269–2009–0–AU–03), 

Canadian Patent 2773665 (HHS 

reference E–269–2009–0–CA–04), 

Chinese Patent 201080049559.3 (HHS 

reference E–269–2009–0–CN–05), 

European Patent 2475398 (HHS 

reference E–269–2009–0–EP–06), as 

validated in France, Germany, Italy, 

Spain and the United Kingdom, Indian 

Patent Application 3197/CHENP/2012 

(HHS reference E–269–2009–0–IN–07), 

Japanese Patent 5795765 (HHS reference 

E–269–2009–0–JP–08), Russian Patent 

Application 2012114005 (HHS reference 

E–269–2009–0–RU–09), and U.S. Patent 

8,936,792 (HHS reference E–269–2009– 

0–US–10); 

U.S. Patent Application 60/969,929 

(HHS reference E–292–2007–0–US–01), 

PCT Application PCT/US2008/075296 

(HHS reference E–292–2007–0–PCT– 

02), Australian Patent 2008296194 (HHS 

reference E–292–2007–0–AU–03), 

Canadian Patent 2698357 (HHS 

reference E–292–2007–0–CA–04), 

European Patent 2197903 (HHS 

reference E–292–2007–0–EP–05) as 

validated in Austria, Belgium, Bulgaria, 

Switzerland, Cyprus, Germany, 

Denmark, Estonia, Spain, Finland, 

France, the United Kingdom, Greece, 

Croatia, Hungary, Ireland, Italy, 

Lithuania, Luxembourg, Latvia, Monaco, 

Malta, the Netherlands, Norway, 

Poland, Portugal, Romania, Slovenia, 

Slovakia, and Turkey, U.S. Patent 

8,871,906 (HHS reference E–292–2007– 

0–US–06), European Patent 2570425 

(HHS reference E–292–2007–0–EP–07) 

as validated in France, Germany, the 

United Kingdom, Italy and Spain, and 

Hong Kong Patent Application 

13106628.2 (HHS reference E–292– 

2007–0–HK–08); 


sradovich on DSK3GMQ082PROD with NOTICES